Dr. Gabrielle Lyon Contributes to New DHA Testosterone Guideline

On September 17, 2026, the Defense Health Agency released an updated Clinical Practice Guideline for testosterone deficiency in male service members, signed by Vice Admiral Darin Via. Among the contributors credited with shaping this guideline is Dr. Gabrielle Lyon, a physician widely known for her work in metabolic health and longevity medicine. Her involvement places LifeSpanMD’s orbit of expertise directly inside a policy document that will affect how hundreds of thousands of service members are screened and treated for hormone-related symptoms.

The core problem the guideline solves

Military populations face a unique diagnostic challenge. Sleep restriction, caloric deficit, intense training, and sustained operations all suppress the hormonal axis that regulates testosterone production, and this suppression usually resolves within days once a service member recovers. That temporary dip looks like hypogonadism on a blood test, but treating it as a permanent deficiency would expose otherwise healthy individuals to unnecessary therapy and risk their fertility. The guideline addresses this directly by requiring specific pre-test conditions before any specimen is considered valid, including a thirty-day buffer after extreme training or illness.

What the new standard requires

• Screening at the Periodic Health Assessment for all men age thirty and older
• Two morning, fasting testosterone draws on separate days below three hundred nanograms per deciliter, paired with a compatible symptom profile
• A mandatory baseline hematocrit before any treatment begins
• Documentation of fertility intent before writing any prescription, since exogenous testosterone can suppress sperm production
• A defined trough target of three hundred to six hundred nanograms per deciliter, with reassessment of the diagnosis if six months of therapy at target produces no symptom benefit

Why Dr. Lyon’s contribution matters

Dr. Lyon has built her reputation on a disciplined, evidence-first approach to metabolic and hormonal health, and that sensibility is visible throughout the guideline. The document is notably conservative about what testosterone therapy can and cannot do, citing the Testosterone Trials showing no benefit for vitality or walking distance, and stating plainly that guidance built around performance enhancement rather than a diagnosed deficiency is not supported by current evidence. That kind of rigor, insisting on both a lab-confirmed deficiency and a compatible symptom profile before treating, reflects the same standard LifeSpanMD applies across its own network of practices.

Why this matters beyond the military

For a field crowded with anecdote and confident marketing claims, this guideline is a useful benchmark for how testosterone deficiency should be evaluated anywhere, not just in uniform. It also addresses erythrocytosis management, deployment considerations for service members on therapy, and fertility-preserving alternatives like hCG and clomiphene for those who are not ready to close the door on having children. The full document, including diagnostic flowcharts and a patient information sheet, is available at www.dha.mil/HHPO.